Medical/Pharmaceuticals
Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by U.S. FDA
NEWARK, Del., Sept. 24, 2020 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth") today announced that its leading candidate, NR082 (rAAV2-ND4, NFS-01 project), was granted an orphan drug designation (ODD) by the U.S. FDA for the treatment of Leber's Hereditary O...
2020-09-25 10:37
656
GenScript ProBio Congratulates XLifeSc on FDA Allowance of IND Application for TCR-T Program
NANJING, China, Sept. 24, 2020 /PRNewswire/ -- On September 24, XiangXue Life Sciences (XLifeSc), a partner of GenScript ProBio, announces FDA allowance of its IND application for TCR-T program (TCRT-ESO-A2). GenScript ProBio extends congratulations on this. This program is China's first TCR-T...
2020-09-24 22:00
1030
Samsung Biologics signs strategic partnership with Kanaph Therapeutics to develop treatment for retinal diseases
INCHEON, South Korea, Sept. 23, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases. According to Kanaph Therapeutics, KNP-301 is designed to ta...
2020-09-24 08:00
638
ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital
SHENZHEN and SHANGHAI, Sept.23, 2020 /PRNewswire/ -- ImmVira Group Company, a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics today announced signing ofUS$10 million Series B Plus strategic financing. This round of financing wi...
2020-09-24 00:09
1201
Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau
* Minoryx will receive an upfront and milestone payments of up to $78 million , as well as double digit royalties on annual net sales * Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-th...
2020-09-23 15:00
649
Alcohol Detection Anklets Showing Promise in NZ
With COVID-19, Incidents of Alcohol Abuse Reportedly on the Rise AUCKLAND, New Zealand, Sept. 22, 2020 /PRNewswire/ -- Alcohol Detection Anklets (ADA) are garnering a lot of attention in New Zealand and Australia for helping alcohol-involved clients refrain from drinking. The anklets use transde...
2020-09-22 04:24
1293
China Pharmaceutical Holdings Co., Ltd. Has Obtained Multiple Certifications for Its Masks
HAIKOU CITY, China, Sept. 21, 2020 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced that the masks produced by ...
2020-09-21 20:30
8061
I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma
SHANGHAI and GAITHERSBURG, Md., Sept. 21, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China ...
2020-09-21 20:00
5050
PharmAbcine expands partnership with Samsung Biologics for PMC-403
DAEJEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular ...
2020-09-21 20:00
1015
WellsCare signs in-store contract with b8ta for IASO
SEOUL, South Korea, Sept. 20, 2020 /PRNewswire/ -- WellsCare, a member company of theBorn2Global Centre, recently signed a store contract with b8ta, a famous American flagship store that is dedicated to innovative products. WellsCare has been an active member of the Born2Global Centre since 2019....
2020-09-20 20:00
1427
Preparation products of Yiling Pharma approved by FDA for launch in the US market
SHIJIAZHUANG, China, Sept. 19, 2020 /PRNewswire/ -- Yiling Pharmaceutical Co., Ltd. announced on Friday that it had received the approvals of the Abbreviated New Drug Applications (ANDA) about Lisinopril Tablets and Acyclovir Capsules, from United States Food and Drug Administration (hereinafter ...
2020-09-19 19:14
1936
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
PLANEGG/MUNICH, Germany and SHANGHAI, China, Sept. 17, 2020 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab (Nasdaq: IMAB) today jointly announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug applic...
2020-09-18 04:05
9747
Dr. Steven Yu Joins ChemPartner as Vice President of Regulated Bioanalysis
SHANGHAI, Sept. 17, 2020 /PRNewswire/ -- Shanghai ChemPartner announced today the appointment ofSteven Yu, Ph.D. as Vice President of Regulated Bioanalysis at the company headquarters inShanghai, China. Dr. Yu has more than 15 years of experience in drug development and extensive expertise in...
2020-09-17 23:01
1303
Expanding Their Existing Strategic Collaboration, GenScript ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc.
NANJING, China, Sept. 17, 2020 /PRNewswire/ -- On September 16th, 2020, GenScript ProBio and REMD Biotherapeutics Inc. (REMD) announced that REMD has licensed a bispecific antibody derived from the Single-domain antibody fused to Monoclonal Ab (SMAB) platform developed by GenScript ProBio. REMD i...
2020-09-17 22:00
1219
Samsung Biologics signs development agreement with Panolos for solid tumor treatment
INCHEON, South Korea, Sept. 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Under this agreement, Samsung Biologics will provide a full scope of its developm...
2020-09-17 08:43
929
Transcenta Successfully Scaled up the Continuous Perfusion Process and Completed GMP Manufacturing of a Novel Bispecific Antibody for Cancer Immunotherapy
SUZHOU, China and HANGZHOU, China, Sept. 15, 2020 /PRNewswire/ -- Transcenta, a global biotherapeutics company, today announced success in scaling up the continuous perfusion process to 200L and completion of GMP production of a bispecific antibody for a Phase 1 clinical study. "This is an impo...
2020-09-15 23:00
1161
Verkada Introduces Environmental Sensor to Provide Enhanced Visibility into Physical Spaces
Sensors seamlessly integrate with Verkada's enterprise video security and access control solutions to deliver real-time insights into buildings Verkada accelerates business growth in Q2 2020 with 65 percent quarter-over-quarter revenue growth amidst COVID-19 pandemic SAN MATEO, California, Sept....
2020-09-15 21:40
1559
PharmAbcine Unveils Olinvacimab's Positive Results from Phase Ib Combination Studies at KSMO 2020
DAEJEON, South Korea, Sept. 14, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) today announced positive data from its two combination trials of olinvacimab, its leading clinical candidate in oncology, with MSD's pembrolizumab at the 13th Annual Meeting of the Korean Society of Medical O...
2020-09-14 20:00
899
Coronavirus Breakthrough: Senhwa Reports First eIND Silmitasertib Treated Severe COVID-19 Patient - Discharged Following Five Days of Treatment
TAIPEI and SAN DIEGO, Sept. 11, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, announced today that the first patient with severe COVID-19 demonst...
2020-09-12 08:34
2496
NaviFUS Launches Neuronavigation-guided Clinical Trial to Open the Blood-Brain-Barrier for Combination FUS-Bevacizumab Therapy in rGBM Patients
TAIPEI, Sept. 11, 2020 /PRNewswire/ -- Genovate Biotech (TPEX:4130) subsidiary andTaiwan-based focused ultrasound (FUS) manufacturer NaviFUS Corporation is pleased to announce the start of its clinical trial (NCT04446416) for the combination of FUS plus bevacizumab therapy. Researchers at Linkou ...
2020-09-11 20:55
2847
Week's Top Stories
Most Reposted
Ruten Japan Launched Global Website
[Picked up by 123 media titles]
2020-09-23 10:00
Klook Launches Klook Live!, Its First-Ever Interactive Livestream Mobile Feature with Encouraging Success, Observes 4 Times Uplift in Conversion Rates
[Picked up by 119 media titles]
2020-09-22 10:35
The Third UNESCO Creative Cities Beijing Summit Highlights Creativity and Innovation
[Picked up by 118 media titles]
2020-09-19 00:36Marriott Bonvoy collaborates with Ascenda to drive growth and build rewards experiences for Marriott Bonvoy Members
[Picked up by 117 media titles]
2020-09-22 09:00
Apis Partners leads US$15 million investment in Prenetics
[Picked up by 113 media titles]
2020-09-18 08:00Most Read
Co-anchor of NBC News' TODAY, co-host of TODAY with Hoda & Jenna and Inspirational Author Hoda Kotb Joins bbcon 2020 Virtual Lineup
2020-09-18 23:02
23211
AirNet Announces Receipt of Deficiency Letter from Nasdaq
2020-09-19 04:30
20977
TuanChe Announces Unaudited Second Quarter 2020 Financial Results
2020-09-18 18:00
15282
Ping An Accelerates Digital innovations in Response to COVID-19
2020-09-18 16:58
15276